Inovio Pharmaceuticals Signs Collaborative Research Agreements With Wistar Institute

Inovio Pharmaceuticals (NASDAQ:INO) has signed collaborative research agreements with the Wistar Institute for preventive and therapeutic DNA-based immunotherapy applications and products for cancers and infectious diseases.
As quoted in the press release:

Inovio will have the exclusive right to in-license new intellectual property developed in this collaboration. Prior to his recent move to Wistar, the underlying technology for Inovio’s DNA-based products was first developed at Dr. Weiner’s UPenn laboratory. Inovio’s license agreements for intellectual property developed at the University of Pennsylvania will not be affected.

Inovio president and CEO, Dr. Joseph Kim, said:

This new agreement with Wistar starts a whole new chapter of Inovio’s R&D leadership in one of the most important emerging medical technologies: DNA-based immunotherapies. We congratulate Dr. Weiner with respect to his multiple new roles at Wistar and the significantly expanded lab and resources available to him to continue pursuing his life’s passion. We look forward to a long and fruitful relationship with this eminent institution to continue advancing cutting edge DNA-based immunotherapies and DNA-based monoclonal antibody technology.

Click here for the full press release.